NovoCure (NVCR) Stock Price, News & Analysis

Company Overview

NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a cancer treatment that uses wearable devices to deliver low-intensity electric fields intended to disrupt cancer cell division. Its products include Optune Gio and Optune Lua, which are used to treat certain cancers.

The company is headquartered in Baar, Switzerland, and serves patients in markets across North America, Europe and Asia. NovoCure was founded in 2000 by Yoram Palti, a medical researcher who developed the TTFields approach.

NovoCure also conducts clinical research to evaluate TTFields in additional cancer types and treatment settings.

Key Stats

• Today's Range: $11.75 to $12.41
• 50-Day Range: $11.81 to $17.94
• 52-Week Range: $9.82 to $21.45
• Volume: 1.53 million shs
• Average Volume: 1.69 million shs
• Market Capitalization: $1.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.33
• Consensus Rating: Hold

NovoCure Stock Analysis - MarketRank™

NovoCure scored higher than 45% of companies evaluated by MarketBeat, and ranked 613th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

NovoCure has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 3 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

NovoCure has a consensus price target of $22.33, representing about 86.3% upside from its current price of $11.99.

Amount of Analyst Coverage

NovoCure has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NovoCure are expected to grow in the coming year, from ($1.09) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NovoCure is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NovoCure is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NovoCure has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.82% of the float of NovoCure has been sold short.

Short Interest Ratio / Days to Cover

NovoCure has a short interest ratio ("days to cover") of 6.02.

Change versus previous month

Short interest in NovoCure has recently increased by 0.71%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NovoCure does not currently pay a dividend.

Dividend Growth

NovoCure does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.08

News Sentiment

NovoCure has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for NovoCure this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for NVCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NovoCure insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.55% of the stock of NovoCure is held by insiders.

Percentage Held by Institutions

84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/29/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NVCR
• CIK: 1645113
• Web: www.novocure.com
• Phone: 441534756700
• Fax: N/A
• Employees: 1,605
• Year Founded: 2000

Price Target and Rating

• Average Price Target for NovoCure: $22.33
• High Price Target: $32.00
• Low Price Target: $15.00
• Potential Upside/Downside: +86.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$136.23 million
• Net Margins: -16.78%
• Pretax Margin: -18.00%
• Return on Equity: -35.81%
• Return on Assets: -15.14%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 2.49
• Quick Ratio: 2.34

Sales & Book Value

• Annual Sales: $725.39 million
• Price / Sales: 1.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.00 per share
• Price / Book: 4.00

Miscellaneous

• Outstanding Shares: 116,916,000
• Free Float: 109,258,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 1.09